BARACK-D Trial: Low-Dose Spironolactone and Cardiovascular Outcomes in Moderate Stage Chronic Kidney Disease The BARACK-D trial is a prospective, randomized, open, blinded endpoint study that investigates the effects of low-dose spironolactone in patients with stage 3b chronic kidney disease (CKD) … Read More
Blog
GLAGOV Trial: Evolocumab on CAD Progression
GLAGOV Trial: Effect of Evolocumab on Coronary Disease Progression in Statin-Treated Patients The GLAGOV trial is a double-blind, placebo-controlled, randomized study designed to assess the impact of PCSK9 inhibition with evolocumab on the progression of coronary atherosclerosis in patients already … Read More
AMBASSADOR Trial: Adjuvant Pembrolizumab in Urothelial Carcinoma
The AMBASSADOR trial is a phase 3 randomized clinical trial aimed at evaluating whether pembrolizumab as adjuvant therapy is more effective than observation in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery. Study Details: Inclusion Criteria: Primary Outcome: Secondary … Read More
2R2 Trial: High-Dose, Short-Duration Rifampicin for TB Prevention
Published in: The LancetAuthors: Ruslami R et al.Publication Year: 2024Source: The Lancet, DOI: 10.1016/S2213-2600(24)00076-6 Objective of the Study:The 2R2 Trial was conducted to compare the safety and treatment completion rates of different doses and durations of rifampicin in patients who … Read More
LMS04 Trial: Doxorubicin-Trabectedin in Leiomyosarcoma
LMS04: Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma Published in: New England Journal of MedicineAuthors: Pautier P et al.Publication Year: 2024Source: N Engl J Med 2024; 391:789-799 Objective of the Study:This trial, LMS04, aimed to refine the treatment strategy for patients … Read More
SWIFT Trials: Depemokimab in Severe Asthma
The SWIFT-1 and SWIFT-2 trials, published in The New England Journal of Medicine in 2024, investigated the efficacy of depemokimab in patients with severe uncontrolled asthma and an eosinophilic phenotype. Key Findings: Conclusion: Depemokimab significantly reduced the annualized rate of … Read More
ARCADIA Trial: Apixaban After Cryptogenic Stroke
The ARCADIA trial, published in JAMA in 2024, compared the efficacy of apixaban versus aspirin in preventing recurrent strokes in patients with cryptogenic stroke and atrial cardiopathy. Key Findings: Conclusion: In patients with cryptogenic stroke and evidence of atrial cardiopathy … Read More
VERONICA-Nigeria Trial: Triple-Pill for Hypertension
The VERONICA-Nigeria trial, published in JAMA in 2024, evaluated the efficacy and safety of a low-dose triple-pill protocol (telmisartan, amlodipine, and indapamide) versus a standard-care protocol for managing hypertension in Black African adults. This parallel-group, open-label, randomized controlled trial involved … Read More
EPIC-CAD Trial: Edoxaban in CAD and AF
The EPIC-CAD trial, recently published in The New England Journal of Medicine, evaluated the efficacy and safety of edoxaban monotherapy compared to dual antithrombotic therapy in patients with stable coronary artery disease (CAD) and high-risk atrial fibrillation (AF). This open-label, … Read More
MATTERHORN Trial Summary: Mitral Valve Repair vs. Surgery in Secondary MR
The MATTERHORN trial, published in The New England Journal of Medicine, investigates the efficacy of transcatheter repair (M-TEER) versus surgical mitral-valve repair for secondary mitral regurgitation (MR) in patients with heart failure. This randomized controlled trial included 208 patients, equally … Read More